Primitive lung cancers are classified as Non-Small Cell Lung Cancer (NSCLC), which accounts for about 80/85% of all lung cancers, and Small Cell Lung Cancer (SCLC) which makes up the remaining 15-20%.
NSCLC today presents the pathologist with varied and demanding diagnostic challenges for multiple reasons:
ALK (Anaplastic Lymphoma Kinase) rearrangements are small inversions on chromosome 2p which may lead to a fusion of parts of EML4 gene with parts of the ALK gene in NSCLC. The resulting fusion protein, with kinase activity, stimulates cell proliferation. Crizotinib, initially developed as a MET inhibitor, has experimentally demonstrated a potent inhibitory activity on ALK.
The analysis of ALK molecular changes is necessary to choose the best therapeutic strategy in selected patients with stage IIIB and IV NSCLC harboring ALK rearrangements who may benefit from ALK- inhibitors treatment. Crizotinib is a selective oral tyrosine kinase inhibitor of ALK and MET which inhibits the tyrosine phosphorylation of ALK.
The Lung Panel can detect in parallel 307 nucleotide variants with respect to the genes EGFR, KRAS, BRAF, PIK3CA, NRAS, ALK, ERBB2, DDR2, MAP2K1 e RET, by MALDI-TOF mass spectrometry combined with Single Base Extension technology. In this way just one sample is sufficient to identify a comprehensive genetic tumour profile and define a targeted treatment strategy.
Tests are performed within 7 working days from sample receipt.